Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Akebia Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
AKBA
Nasdaq
2834
https://akebia.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Akebia Therapeutics Inc
Akebia Therapeutics Provides Update on Regulatory Process for Vadadustat
- Mar 30th, 2023 12:30 pm
Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder Meeting
- Mar 24th, 2023 12:30 pm
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2022 Earnings Call Transcript
- Mar 13th, 2023 6:51 am
Q4 2022 Akebia Therapeutics Inc Earnings Call
- Mar 10th, 2023 3:42 am
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
- Mar 9th, 2023 1:45 pm
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
- Mar 9th, 2023 12:30 pm
Akebia Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Discuss Recent Business Highlights
- Mar 2nd, 2023 1:30 pm
Akebia Receives Positive CHMP Opinion in Europe for Vafseoâ„¢ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
- Feb 23rd, 2023 9:05 pm
The Petri Dish: Blindness drug approved; Moderna strikes gene-editing deal
- Feb 23rd, 2023 10:34 am
Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
- Feb 21st, 2023 11:30 am
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Feb 1st, 2023 9:05 pm
Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA
- Dec 22nd, 2022 1:45 pm
Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
- Nov 22nd, 2022 9:05 pm
Akebia Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags
- Nov 9th, 2022 11:10 am
Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates
- Nov 3rd, 2022 10:45 pm
Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
- Nov 3rd, 2022 8:05 pm
Akebia Therapeutics to Report Third Quarter Financial Results and Highlight Recent Company Milestones
- Oct 27th, 2022 12:30 pm
Akebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2022
- Oct 21st, 2022 12:30 pm
Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference
- Sep 1st, 2022 12:30 pm
Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study
- Aug 5th, 2022 3:12 pm
Scroll